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In summary, although a complete
understanding of the mechanisms leading
to palmoplantar keratoderma and nail
dystrophy in PC has yet to be achieved,
Krt16-null mice provide additional insights
into this process and highlight the impor-
tance of KRT16 in the normal structure
and function of palmoplantar epithelia.
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IL-33: A Novel Danger Signal System in
Atopic Dermatitis
Ferda Cevikbas1 and Martin Steinhoff1
IL-33 is a newly recognized cytokine of the IL-1 cytokine family that has recently been
attributed to the epithelial ‘‘alarmin’’ defense system. IL-33 is released by the epithelial
cells in various tissues and organs, including keratinocytes, endothelial cells, and
immune cells. Recent reports have suggested that IL-33 might be a critical part of the
innate immunity, although its precise role is as yet poorly understood. In several organs,
IL-33 appears to drive T helper type 2 (Th2) responses, suggesting roles in allergic and
atopic diseases, as well as in fibrosis. IL-33 exerts its effects by activating the ST2
(suppression of tumorigenicity 2)/IL-1 aR receptor on different types of cells, including
mast cells and Th2 cells. The ST2 receptor is either expressed on the cell surface or shed
from these cells (soluble ST2, sST2), thereby functioning as a ‘‘decoy’’ receptor. After
binding to its receptor, IL-33 activates NF-kB, suggesting that it regulates the outcome of
diseases such as atopic dermatitis. On the other hand, several studies have reported on
the inhibitory effects of sST2 in inflammatory and fibrotic diseases, suggesting that IL-33/
ST2 is a unique cytokine with potential pro- and anti-inflammatory effects.
Journal of Investigative Dermatology (2012) 132, 1326–1329. doi:10.1038/jid.2012.66
Atopic dermatitis (AD) is a common
chronic inflammatory skin disease char-
acterized by an early T helper type 2
(Th2) ‘‘immune signature’’: patients suffer
from relapsing eczematous and occasion-
ally generalized (erythroderma) lesions
associated with severe pruritus (Bonness
and Bieber, 2007; Boguniewicz and
Leung, 2011). Scratching reactions to
pruritus typically exacerbate the inflam-
matory skin reactions (Hong et al., 2011).
The key events in AD may be subdivided
as an interplay among (1) infiltrating
immune cells (Th2 cells and—later—
Th1 cells, macrophages, dendritic cells,
mast cells, and eosinophils); (2) skin-
resident keratinocytes and endothelial
cells; and (3) activated (‘‘hypersensitive’’)
peripheral sensory nerves. The multicel-
lular action is believed to orchestrate
disease onset and progression (Steinhoff
et al., 2006; Cevikbas et al., 2007). Un-
fortunately, current AD treatments, which
suppress inflammation broadly (e.g.,
steroids, cyclosporin A), are hampered
by effects on other cells and pathways
that are unrelated to the disease.
The adaptive and innate immune sys-
tems have important and bidirectional
roles in the pathophysiology of AD
(Bieber, 2008; Elias and Steinhoff, 2008).
Cytokines such as IL-4 and IL-13 regulate
proinflammatory responses of the adap-
tive immune response in early phases of
AD by regulating Th2 activation; thus,
they are considered optimal targets for
therapies. Keratinocytes, however, as part
of the innate immune defense, also
contribute to the inflammatory reactions
and immune responses in AD by regu-
lating the release of cytokines, chemo-
kines, proteases, and bioactive lipids.
Upon stimulation by allergens, toxins,
or infectious agents, keratinocytes are
capable of initiating a cross-talk bet-
ween the adaptive and innate immune
responses by activating T cells in
patients with AD through the release of
key molecules (Homey et al., 2006).
Thus, cytokines such as IL-25 and
chemokines such as TSLP (thymic
stromal lymphopoietin) or CCL27 have
important roles in this interactive net-
work (Carmi-Levy et al., 2011).
Recent evidence points to a role for
the IL-33/ST2 (suppression of tumorigeni-
city 2) pathway in epithelial integrity,
allergic immune responses, inflamma-
tion, autoimmunity, and fibrosis, which
are just several examples (Moussion
et al., 2008; Ivanov et al., 2010; Rankin
et al., 2010). In skin, the functional role
of this newly recognized IL-33/ST2
pathway has gained attention. The
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findings thus far indicate that the release
of IL-33 by keratinocytes, endo-
thelial cells, or immune cells activates
the IL-33 receptor ST2 on keratinocytes,
fibroblasts, mast cells, or other immune
cells, leading to the expression of factors
implicated in several inflammatory path-
ways (Pushparaj et al., 2009; Liew et al.,
2010). This IL-33/ST2-induced immune
regulation may have a crucial role in
adaptive as well as innate immune
responses in skin.
IL-33 has important roles in the
pathogenesis of several Th2-biased
inflammatory conditions and allergic
reactions (Verri et al., 2008; Figure 1).
An alternative transcript from the ST2
locus encodes a soluble form of the ST2
receptor (sST2), which acts as a natural
IL-33 antagonist (decoy receptor). IL-33–
dependent activation of ST2 signaling
leads to activation of the signaling path-
ways signal transducer and activator
of transcription 5, mitogen-activated
protein kinase, Akt, and NF-kB (Guo
et al., 2009; Ivanov et al., 2010; Ali
et al., 2011; Funakoshi-Tago et al.,
2011), most of which ultimately have
roles in the pathogenesis of AD. The
mature form of IL-33 is released into the
cytoplasm and subsequently stimulates
T cells, mast cells, or keratinocytes.
Similar to IL-1, full-length IL-33 can act
as a transcription factor by trafficking
into the nucleus, where it modulates
several inflammatory responses (Carriere
et al., 2007).
Intriguingly, IL-33 expression is upreg-
ulated in keratinocytes and endothelial
cells in AD (Oboki et al., 2010). Inject-
ion of recombinant IL-33 into mouse skin
in vivo is sufficient to cause infil-
tration of T cells, macrophages, and
eosinophils, all of which are immune
cells that express the functional ST2/
IL-1R4 receptor complex (Kroeger et al.,
2009; Rankin et al., 2010; Anthony et al.,
2011; Eiwegger and Akdis, 2011; Ohno
et al., 2011; Zaiss et al., 2011). Further-
more, IL-33 stimulation leads to the
release of Th2-associated mediators,
suggesting that IL-33 might fulfill a
crucial role in Th2-associated diseases
such as AD. In summary, considerable
evidence points to a key contribution of
the IL-33/ST2 pathway in inflammatory
skin diseases, including AD. In the future,
it will be important to understand the
precise roles of the different subforms of
IL-33 (secreted, intracellular) and ST2
(transmembrane, decoy) in skin.
Savinko et al. (this issue, 2012) inves-
tigated the expression profiles of IL-33
and ST2 in different mouse models of
atopic-like dermatitis (AD), emphasizing
a regulatory role for this novel cytokine
pathway. In a translational setting, the
authors also quantified the messenger
RNA levels for IL-33 and ST2 in lesional
and nonlesional human skin. Via immu-
nohistochemistry, the authors restricted
the distribution of IL-33þ cells to supra-
basal keratinocytes. The ST2þ cell popu-
lation was found to be dermal and
epidermal in origin, although a precise
characterization of the ST2þ dermal cells
is still lacking. Different allergens, when
applied topically (ovalbumin, house dust
mites, or staphylococcal enterotoxin B) to
mice, led to the upregulation of IL-33 and
ST2 messenger RNA expression. These
results indicate that IL-33 as well as its
receptor may be induced in AD when
exposed to AD trigger factors. Whether
these results reflect the human situation
remains unknown. Intriguingly, topical
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Figure 1. Potential role of IL-33 and ST2 (suppression of tumorigenicity 2) in skin inflammation and
pathophysiology of atopic dermatitis. Trigger factors such as allergens, bacteria, mechanical injury, and
exogenous proteases induce the release of IL-33, IL-25, and thymic stromal lymphopoietin (TSLP) from
keratinocytes. IL-33, alone or in combination with other cytokines and chemokines, activates mast cells,
dendritic cells, and (potentially) lymphocytes of innate lineage in inflamed skin. Activation of mast cells
regulates the function of dendritic cells, eosinophils, T cells, and nerves (not shown) via release of
cytokines, chemokines, growth factors, proteases, and leukotrienes, for example. Via the IL-33–induced
release of IL-25 and IL-18, dendritic cells regulate the function of T helper type 2 (Th2) cells and B cells
(early) and (probably later) Th1 cells. Via IL-33 induction, innate lymphoid cells (ILCs) regulate Th2-driven
immune responses in various organs. The role of these potentially important cells in Th2 regulation has not
been verified in skin. ILCs have been described to be important in the early stage of immune signaling and
probably enhance the Th2 immune response pathway in the skin. The arrows illustrate the interaction
among the various immune cells and their cell-specific secretion products involved in inflammatory skin
diseases, including atopic dermatitis. Thus, IL-33 may be involved in orchestrating early inflammatory
responses in the onset and perpetuation of atopic dermatitis. His, histamine; Lkt, leukotriene; OX40 (gp34),
a member of the TNF superfamily; TNF-a, tumor necrosis factor-a (Modified from Carmi-Levi et al., 2011).
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treatment with calcineurin inhibitors such
as tacrolimus, a topical drug used widely
to treat AD, reduced the expression levels
of both IL-33 and ST2. Combined stimu-
lation with pro-inflammatory cytokines
such as tumor necrosis factor (TNF)-a
and IFN-g caused an increase in IL-33
protein expression in cultured fibroblasts
and HaCaT keratinocytes. The possibility
of translating these observations to
humans is unlikely because IL-33 appears
to be an early cytokine in the inflamma-
tory cascade, and neither TNF-a nor IFN-
g has important roles in the early phases
of AD. Thus, the role of the IL-33/ST2
pathway in early and late inflammatory
responses remains uncertain, and its
impact during the different phases of
inflammation and immune defense
remains controversial, depending on the
tissues and species being studied.
Savinko et al. (2012) also emphasized
a potential interaction between kera-
tinocyte-derived IL-33 and mast cells,
which are critical in AD pathogenesis,
showing that bone marrow–derived mast
cells activated by IgEþ allergens increase
the expression levels of ST2 and IL-33.
The report analyzes the expression pro-
files of IL-33 and ST2 for a well-chosen
set of allergens believed to be important
trigger factors for AD.
Thus far, IL-33 has been implicated
in pro- as well as anti-inflammatory
processes in various tissues and cells
(Haraldsen et al., 2009; Kroeger et al.,
2009). Hence, a key issue is to identify
when IL-33 acts as a pro-inflammatory
molecule and when it acts as an anti-
inflammatory molecule during different
stages of an immune response. For
example, in the intestine, IL-33 stimu-
lates the induction of Th2-associated
cytokines (IL-4, IL-9, IL-13) during para-
site infection and prevents Th1-polarized
cell responses. Interestingly, exogenous
IL-33 also induces TSLP messenger RNA,
another early signaling molecule in the
epidermis (Humphreys et al., 2008). In
human mastocytoma cells and bone
marrow–derived mast cells, IL-33 induces
IL-1b, TNF-a, MCP-1 (monocyte chemo-
attractant protein-1), and PGD2 (prosta-
glandin D2) production and increases IL-6
and IL-1b messenger RNA expression
in vitro (Moulin et al., 2007). In some of
these models, the proinflammatory effects
of IL-33 are inhibited by sST2 acting as
a decoy receptor.
Although poorly studied, new evidence
points to an important role for the IL-33/
ST2 pathway in many skin diseases,
including AD in humans (Pushparaj
et al., 2009). In a mouse model of skin
inflammation and UVB-induced derma-
titis, IL-33 levels were found to be
enhanced at both the RNA and protein
levels. In vitro, UVB and oxPAF (oxi-
dized alkyl acyl phosphocholines) increa-
sed IL-33 expression in keratinocytes and
fibroblasts. Notably, IL-33 application in
a model of Th1-mediated acute contact
hypersensitivity markedly suppressed its
proinflammatory effects. Thus, IL-33 may
be an important early danger signal in
response to UV radiation (Byrne et al.,
2011).
An exciting recent observation was the
characterization of innate lymphoid cells
(ILCs) as an important link in the com-
munication between innate and adaptive
immunity (Saglani, 2011). ILCs are
crucial in organizing inflammation and
immunity in the lung, intestine, and
adipose tissue. Together, these in vitro
and in vivo findings implicate a role for
IL-33 as an early danger-sensing mole-
cule during the impairment of tissue
integrity, as observed in inflammation,
allergy, and tissue injury (Figure 1). For
example, Monticelli et al. (2011) showed
that ILCs in the lung expressing CD90,
IL-2, CD25, CD127, and ST2 accumu-
late after influenza A infection. Notably,
depletion of ILCs resulted in loss of epi-
thelial integrity and impaired remodeling
and airway function, at least in part via
ST2 activation. This indicates that ILCs
may be critical for restoring epithelial
integrity and tissue homeostasis, partly
via ST2 activation by IL-33.
The work by Savinko et al. (2012)
expands our understanding of the
complex interaction between the skin’s
innate and adaptive immune responses.
Nevertheless, important questions in our
understanding of the IL-33/ST2 signaling
system in skin inflammation and
immune regulation remain. (1) Where
are IL-33 and ST2 expressed under
physiological and pathophysiological
conditions in the skin? (2) How does
this cytokine system signal during acute
and chronic inflammation? (3) When
does IL-33 exert its pro- and anti-
inflammatory effects, and when and
why does the switch occur? (4) How is
IL-33 regulated in skin cells? (5) When is
IL-33 present in its mature form in skin
cells? (6) What is the physiological
role and what is the pharmacological
benefit of sST2 release? (7) What is the
functional role of IL-33 and ST2 in the
early and late phases of AD? Answers to
these questions will open a new chapter
in our understanding of the complex
interplay of the innate and adaptive
immune defense in AD, opening possi-
bilities for novel targeted therapies.
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Clinical Implications
 The newly recognized cytokine IL-33 influences atopic dermatitis variously,
up and down.
 The mechanism of action establishes IL-33/ST2 as a potential target to
treat atopic dermatitis.
 Lymphocytes of innate immunity may be regulated by IL-33 in human
skin disease.
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Toward Personalized Medicine in
Scleroderma: Classification of
Scleroderma Patients into Stable
‘‘Inflammatory’’ and ‘‘Fibrotic’’
Subgroups
Andrew Leask1
There is no universally agreed-upon treatment for the fibrosis of scleroderma.
Recently, much information has been generated relating to the fundamental
mechanisms underlying this disease. Partly based on these observations, both
anti-inflammatory and anti-fibrotic agents have been considered as possible
therapies. However, this information has not been successfully translated into
clinical practice. In this issue, Pendergrass et al. use genome-wide expression
profiling to provide valuable insights into scleroderma. Previously, the authors
showed that morphea and ‘‘limited’’ scleroderma patients and a small subset of
diffuse scleroderma (dSSc) patients express an ‘‘inflammatory’’ profile, whereas
the majority of dSSc patients express a ‘‘fibroproliferative’’ profile. In the current
study, the investigators show that the gene expression profile of these patients is
fixed over time; i.e., in contrast to a previously held belief, the inflammatory
patients do not go on to become fibrotic, and vice versa. These data suggest that
expression profiling might be used to design clinical trials for scleroderma. The
inflammatory patients might be treated with anti-inflammatory agents, whereas
fibroproliferative patients might be treated with antifibrotic agents.
Journal of Investigative Dermatology (2012) 132, 1329–1331. doi:10.1038/jid.2012.67
A connective-tissue disorder of unknown
etiology, scleroderma (also called sys-
temic sclerosis or SSc), is a multisystem
disease characterized by the presence of
autoantibodies, vascular damage, and
organ fibrosis (Abraham and Varga,
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